Sustained virologic response at 24 weeks after the end of treatment is a better predictor for treatment outcome in real-world HCV-infected patients treated by HCV NS3/4A protease inhibitors with peginterferon plus ribavirin

International Journal of Medical Sciences

Volumn 13, Issue 4, 2016, Pages 310-315

  Kanda, Tatsuo ^a   Nakamoto, Shingo ^a   Sasaki, Reina ^a   Nakamura, Masato ^a   Yasui, Shin ^a   Haga, Yuki ^a   Ogasawara, Sadahisa ^a   Tawada, Akinobu ^a   Arai, Makoto ^a   Mikami, Shigeru ^b   Imazeki, Fumio ^c   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kikkoman General Hospital   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Direct acting antivirals; HCV RNA; Hepatitis C; Sustained virologic response

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPACIVIRIN INHIBITOR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMEPREVIR; TELAPREVIR; VIRUS RNA; OLIGOPEPTIDE; PROTEINASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; ADVERSE DRUG REACTION; ANEMIA; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN CELL; JAPANESE (PEOPLE); JAUNDICE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PREDICTION; RASH; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RNA ANALYSIS; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER GASTROINTESTINAL BLEEDING; AGED; CHRONIC HEPATITIS C; COMBINATION DRUG THERAPY; DRUG EFFECT; GENETICS; GENOTYPE; HEPACIVIRUS; MIDDLE AGED; PATHOGENICITY; PATHOLOGY; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; AGED; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROTEASE INHIBITORS; RIBAVIRIN; RNA, VIRAL; SIMEPREVIR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84963533549     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.14953     Document Type: Article

References (21)

1. Saito I, Miyamura T, Ohbayashi A, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A. 1990; 87: 6547-9.
2. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997; 26(31): 34-38.
3. Ueno Y, Sollano JD, Farrell GC. Prevention of hepatocellular carcinoma complicating chronic hepatitis C. J Gastroenterol Hepatol. 2009; 24: 531-6.
4. George SL, Bacon BR, Brunt EM, et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009; 49: 729-38.
5. Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int. 2010; 4: 548-61.
6. Omata M, Kanda T, Yu ML, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int. 2012; 6: 409-35.
7. Kanda T, Imazeki F, Wu S, et al. The assessment of serum hepatitis C virus RNA 12 weeks after the end of treatment using TaqMan polymerase chain reaction is less relevant than after 24 weeks for predicting sustained virological response. Hepatology. 2011; 54: 1482.
8. Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010; 51: 1122-6.
9. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013; 368: 1867-77.
10. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014; 370: 1879-88.
11. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014; 370: 1983-92.
12. Kanda T, Imazeki F, Yonemitsu Y, et al. Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test. J Viral Hepat. 2011, 18: e292-7.
13. Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009; 49: 1954-61.
14. Miyamura T, Kanda T, Nakamoto S, et al. Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients. PLoS One. 2011; 6: e28617.
15. Miyamura T, Kanda T, Nakamoto S, et al. IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens. Int J Hepatol. 2014; 2014: 723868.
16. Kanda T, Nakamura M, Sasaki R, et al. Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon alpha-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype. Case Rep Gastroenterol. 2015; 9: 215-20.
17. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015; 15: 645-53.
18. Buti M, Gordon SC, Zuckerman E, et al. Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE. Clin Infect Dis. 2016; 62: 32-6.
19. Ogawa E, Furusyo N, Dohmen K, et al. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure. J Viral Hepat. 2015; 22: 992-1001.
20. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015; 62: 932-54.
21. Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology. 2013; 144: 1450-5.